.
BioEnterprise

Abeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101

Abeona Therapeutics receives Orphan Drug Designation in the European Union for its EB-101 gene therapy program for patients with recessive dystophic epidermolysis bullosa.

Read More  >